<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841786</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300002442</org_study_id>
    <nct_id>NCT03841786</nct_id>
  </id_info>
  <brief_title>Effect of Phosphorus Additives on the Metabolome in Healthy Adults</brief_title>
  <official_title>Effect of Phosphorus Additives on the Metabolome in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of phosphorus supplementation on the human metabolome. The
      investigators will do so by conducting a cross-over study in healthy adults consuming a study
      diet (normal diet supplemented by neutral sodium phosphorus, 1 gram/day) for seven days and a
      control diet (normal diet supplemented by sodium and potassium chloride only) for seven days
      with a 28 day wash-out period in between. Untargeted metabolomic analyses will be done in
      serum samples obtained at the end of each diet period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phosphorus is an essential micronutrient involved in a number of key biological processes.
      Excess phosphorus intake is linked to hypertension, heart failure, and disorders of bone and
      mineral metabolism. This has critical implications for public health in that dietary
      phosphorus consumption in the US far exceeds current recommendations for daily intake.

      Most studies that examined the adverse effects of excess phosphorus intake have focused on
      single tissue or cell specific processes. However, a full understanding of the systemic
      impact of nutritional phosphorus intake requires a more integrated biologic approach. The
      human metabolome represents the final end-product of the omics cascade, which can serve as an
      integrated measure of the total biological response to dietary exposures. Few studies have
      examined the impact of nutritional phosphorus intake on the human metabolome. Expanding the
      understanding of the effect of diet phosphorus on the metabolome has the potential to
      identify novel phosphorus-responsive pathways that may be therapeutic targets for reducing
      the development of hypertension, cardiovascular and kidney disease. The investigators will
      test the following hypothesis: consumption of a high phosphorus diet will result in
      significant changes in circulating metabolites associated with cardiometabolic health.

      This hypothesis is supported by published and preliminary studies showing that high
      phosphorus intake alters metabolic pathways with a wide variety of pathophysiologic effects.
      In the current application, the investigators propose to build on this work by investigating
      the effect of phosphorus consumption on the human metabolome using an untargeted approach.
      The investigators will do so by conducting a cross-over study in healthy adults consuming a
      study diet (normal diet supplemented by neutral sodium phosphorus, 1 gram/day) for seven days
      and a control diet (normal diet supplemented by sodium and potassium chloride only) for seven
      days with a 28 day wash-out period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Eligible subjects will consume a phosphorus supplemented diet (study diet) and a sodium and potassium chloride supplemented diet (control diet), with cross-over to the other diet following a 24-day wash-out period. The order in which the diets are consumed will be randomly assigned.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Untargeted Metabolomics</measure>
    <time_frame>7 days</time_frame>
    <description>Untargeted metabolomics will be the primary endpoint and will be performed on serum samples obtained for all participants at the end of each dietary period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor 23 (FGF23)</measure>
    <time_frame>7 days</time_frame>
    <description>FGF23 concentrations will be measured at the end of each dietary period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Control diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphorus-supplemented study diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phosphorus-supplemented study diet</intervention_name>
    <description>Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.</description>
    <arm_group_label>Phosphorus-supplemented study diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Diet</intervention_name>
    <description>Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week</description>
    <arm_group_label>Control diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers, aged 18 - 45 years with normal kidney function (estimated
             glomerular filtration rate &gt; 60 ml/min/1.73m2).

        Exclusion Criteria:

          -  abnormal urinalysis—presence of hematuria, proteinuria, or leukocyturia. pregnancy or
             breast-feeding

          -  Medical conditions impacting phosphate metabolism—primary hyperparathyroidism;
             gastrointestinal malabsorption disorders such as Crohn's Disease, ulcerative colitis,
             celiac disease, or liver dysfunction; hyper- or hypothyroidism; irregular menses for
             female subjects.

          -  Medications known to affect phosphorus metabolism— current use of phosphorus
             supplements, high-dose or activated vitamin D compounds, regular antacid or laxative
             use, anticonvulsants.

          -  Hyper- or hypophosphatemia (≥ 4.6 mg/dl or ≤ 2.5 mg/dl respectively), hyper- or
             hypocalcemia (≥ 10.6 or ≤ 8.5 mg/dl respectively), or severe anemia (hemoglobin &lt; 8
             g/dl for women and &lt; 9 g/dl for men), hyperkalemia (potassium &gt; 5.0 mmol/L).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orlando Gutierrez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shejuti Paul</last_name>
    <phone>2564439051</phone>
    <email>paul0217@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra McPherson</last_name>
    <phone>205-975-9743</phone>
    <email>alexlm@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Orlando Gutierrez, MD, MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208-18.</citation>
    <PMID>15284307</PMID>
  </reference>
  <reference>
    <citation>Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007 May 14;167(9):879-85.</citation>
    <PMID>17502528</PMID>
  </reference>
  <reference>
    <citation>Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res. 2009;32(1):37-44. doi: 10.1159/000203348. Epub 2009 Feb 20.</citation>
    <PMID>19229116</PMID>
  </reference>
  <reference>
    <citation>Ix JH, De Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol. 2009 Mar;4(3):609-15. doi: 10.2215/CJN.04100808. Epub 2009 Feb 11.</citation>
    <PMID>19211667</PMID>
  </reference>
  <reference>
    <citation>Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005 Feb;16(2):520-8. Epub 2004 Dec 22.</citation>
    <PMID>15615819</PMID>
  </reference>
  <reference>
    <citation>Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005 Oct 25;112(17):2627-33. Erratum in: Circulation. 2007 Dec 4;116(23):e556.</citation>
    <PMID>16246962</PMID>
  </reference>
  <reference>
    <citation>Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008 Jun;19(6):1092-105. doi: 10.1681/ASN.2007070760. Epub 2008 Apr 16.</citation>
    <PMID>18417722</PMID>
  </reference>
  <reference>
    <citation>Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y, Takeda E. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol. 2009 Jul;20(7):1504-12. doi: 10.1681/ASN.2008101106. Epub 2009 Apr 30.</citation>
    <PMID>19406976</PMID>
  </reference>
  <reference>
    <citation>Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009 Feb;20(2):381-7. doi: 10.1681/ASN.2008040349. Epub 2008 Dec 10.</citation>
    <PMID>19073826</PMID>
  </reference>
  <reference>
    <citation>Saab G, Whooley MA, Schiller NB, Ix JH. Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. Am J Kidney Dis. 2010 Sep;56(3):496-505. doi: 10.1053/j.ajkd.2010.03.030. Epub 2010 Jun 26.</citation>
    <PMID>20580478</PMID>
  </reference>
  <reference>
    <citation>Gutiérrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the &quot;trade-off&quot; hypothesis. Clin J Am Soc Nephrol. 2010 Sep;5(9):1710-6. doi: 10.2215/CJN.02640310. Epub 2010 May 27. Review.</citation>
    <PMID>20507957</PMID>
  </reference>
  <reference>
    <citation>Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 2007 Jul-Aug;20(4):295-301. Review.</citation>
    <PMID>17635818</PMID>
  </reference>
  <reference>
    <citation>Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial. 2003 May-Jun;16(3):186-8.</citation>
    <PMID>12753675</PMID>
  </reference>
  <reference>
    <citation>Gutiérrez OM, Luzuriaga-McPherson A, Lin Y, Gilbert LC, Ha SW, Beck GR Jr. Impact of Phosphorus-Based Food Additives on Bone and Mineral Metabolism. J Clin Endocrinol Metab. 2015 Nov;100(11):4264-71. doi: 10.1210/jc.2015-2279. Epub 2015 Aug 31.</citation>
    <PMID>26323022</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Orlando M. Gutierrez, MD, MMSc</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Metabolome</keyword>
  <keyword>Phosphorus</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

